within Pharmacolibrary.Drugs.ATC.G;

model G03EA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.07,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03EA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combination drug containing testosterone and estrogen, mainly used for hormone replacement therapy (HRT) in menopausal women, andropause, and in transgender hormone therapy. Not routinely used as a combination in modern practice; older formulations were used for menopausal symptoms and hypogonadism.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies found specifically for the combined testosterone and estrogen product (G03EA02) in the scientific literature. Parameter estimates are based on typical literature values for oral estrogen and oral testosterone therapies.</p><h4>References</h4><ol><li><p>Zhang, H, et al., &amp; Streisand, JB (2002). Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 41(9) 661–680. DOI:<a href=\"https://doi.org/10.2165/00003088-200241090-00003\">10.2165/00003088-200241090-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12126458/\">https://pubmed.ncbi.nlm.nih.gov/12126458</a></p></li><li><p>Zimmerman, Y, et al., &amp; Fauser, BC (2013). The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. <i>The European journal of contraception &amp; reproductive health care : the official journal of the European Society of Contraception</i> 18(6) 489–500. DOI:<a href=\"https://doi.org/10.3109/13625187.2013.822061\">10.3109/13625187.2013.822061</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23944295/\">https://pubmed.ncbi.nlm.nih.gov/23944295</a></p></li><li><p>Snyder, CN, et al., &amp; Amory, JK (2010). Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism. <i>Journal of andrology</i> 31(6) 527–535. DOI:<a href=\"https://doi.org/10.2164/jandrol.109.009746\">10.2164/jandrol.109.009746</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20378927/\">https://pubmed.ncbi.nlm.nih.gov/20378927</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03EA02;
